Petros executes initial test for app comprehension for STENDRA FDA pathway

Petros Pharmaceuticals announced results of an initial study to determine consumer comprehension of the messaging in its App Technology, which has unique differences from the current Drug Facts Label. Of the 31 objectives, 29 scored greater than90% comprehension Point Estimate 30 scored greater than86.7% comprehension PE, and all scored greater than80% comprehension PE. 21 scored 100% comprehension PE. The results of the study demonstrated that the vast majority of communications were well understood by the patients in the study. The App Comp study evaluated consumer understanding of 31 distinct messages that appeared either on a desktop or a mobile device. The expected threshold of understanding was 90%, of which only two were evaluated lower, as scored by PE. The results of this study, while supportive as a standalone study of the functionality of the App Technology, were designed to provide guidance to the Company in connection with the development of a larger-scale App Comp with a larger patient population, estimated to include about 400 patients. The Company expects to receive results from the larger study, which is currently underway, by Q4 2024.